Physician profile
Eileen Levy
NPI 1710024211
$3,088.96
in general payments reported to CMS, 2019-2025
21 companies · $783 in 2025
The $783 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $728 · 2022: $574 · 2023: $570 · 2024: $435 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $640.35 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $585.87 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $272.58 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $247.12 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $234.84 | 2021-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $213.66 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $197.66 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $147.24 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $103.75 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $91.94 | 2021-2024 | Ingrezza |
| Corium, LLC | $62.48 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $60.11 | 2021-2025 | Fanapt |
| Merck Sharp & Dohme LLC | $39.78 | 2022 | |
| Eisai INC. | $32.20 | 2021 | |
| Harmony Biosciences LLC | $31.64 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $29.45 | 2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $22.74 | 2021 | |
| Almatica Pharma LLC | $21.41 | 2022 | |
| Bausch Health US, LLC | $21.04 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.28 | 2024 | Quviviq |
| Alfasigma USA, INC. | $13.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.